BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) shares traded up 9.2% during mid-day trading on Friday . The company traded as high as $23.28 and last traded at $23.47. 216,157 shares were traded during mid-day trading, a decline of 45% from the average session volume of 393,166 shares. The stock had previously closed at $21.50.
Wall Street Analyst Weigh In
A number of research firms recently commented on BLFS. Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of BioLife Solutions in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $31.17.
Check Out Our Latest Stock Analysis on BioLife Solutions
BioLife Solutions Price Performance
The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock has a market capitalization of $1.12 billion, a PE ratio of -22.17 and a beta of 1.82. The company's fifty day simple moving average is $22.56 and its two-hundred day simple moving average is $25.05.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. The business had revenue of $23.94 million during the quarter, compared to analysts' expectations of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. As a group, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.
Insider Activity
In related news, CFO Troy Wichterman sold 25,687 shares of the company's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the transaction, the chief financial officer now directly owns 189,242 shares in the company, valued at approximately $4,288,223.72. This represents a 11.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sarah Aebersold sold 1,091 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $27,275.00. Following the transaction, the insider now owns 58,816 shares in the company, valued at $1,470,400. This trade represents a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,756 shares of company stock valued at $1,660,535 over the last 90 days. Insiders own 2.20% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of BLFS. Steward Partners Investment Advisory LLC purchased a new stake in BioLife Solutions in the fourth quarter valued at approximately $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BioLife Solutions in the 4th quarter valued at $31,000. State of Wyoming grew its stake in shares of BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 1,490 shares during the period. US Bancorp DE increased its holdings in shares of BioLife Solutions by 243.7% during the 1st quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,528 shares during the last quarter. Finally, 1620 Investment Advisors Inc. raised its position in shares of BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after buying an additional 675 shares during the period. Institutional investors and hedge funds own 93.24% of the company's stock.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
